Comparison of Pharmacokinetic Similarity, Immunogenicity, and Safety of Ustekinumab and BAT2206 in Healthy Chinese Male Subjects in a Double-Blind, Randomized, Single-Dose, Parallel-Group Phase I Trial-Reference-Cited by-同舟云学术

Comparison of Pharmacokinetic Similarity, Immunogenicity, and Safety of Ustekinumab and BAT2206 in Healthy Chinese Male Subjects in a Double-Blind, Randomized, Single-Dose, Parallel-Group Phase I Trial

Published:2022-11-22 Issue:1 Volume:37 Page:89-98
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Wu Min,Li Xiaojiao,Yang Deming,Wang Meng,Zhang Hong,Li Cuiyun,Mai Jiajia,Yang Lizhi,Qi Yunpeng,Yu Jin-Chen,Yang Xiaolei,Wang Zhaohe,Gu Cailing,Ding Yanhua

Funder

Capital Construction Funds within the provincial budget in 2020

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s40259-022-00563-5.pdf

Reference12 articles.

1. Tam A, Geier KA. Psoriatic arthritis. Orthop Nurs. 2004;23(5):311–4.

2. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34(3):J314–21.

3. Ding X, Wang T, Shen Y, Wang X, Zhou C, Tian S, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012;22(5):663–7.

4. Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, et al. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol. 2005;52(1):23–6.

5. Wu Y, Chen J, Li YH, Ma GZ, Chen JZ, Gao XH, et al. Treatment of psoriasis with interleukin-12/23 monoclonal antibody: a systematic review. Eur J Dermatol. 2012;22(1):72–82.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of SB17 and reference ustekinumab in healthy adults: A randomized, double-blind, single-dose, phase I study;Int. Journal of Clinical Pharmacology and Therapeutics;2024-05-01

2. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis;Clinical Pharmacokinetics;2024-01-27